NVS NVS
Company Profile ↓Company Overview
NVS (NVS) is a publicly traded company listed on with a market capitalization of $326.24B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 30.3%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 21.1%.
Net profit has compounded at 26.2% per year over the last five years.
Maintains a net profit margin of 24.7%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $56.67B (+9.6% YoY); net profit $13.98B.
- Trailing 12 Months Year-on-year growth — revenue +9.6%, earnings +17.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.2%, profit CAGR 26.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.25% |
| 1 Year: | 9.57% |
Compounded Profit Growth
| 5 Years: | 26.22% |
| 1 Year: | 17.11% |
Stock Price Performance
| 1 Year: | +35.06% |
| 6 Months: | +6.19% |
| 3 Months: | +6.14% |
| 1 Month: | -1.65% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 30.3%.
- Healthy ROCE of 21.1%.
- Excellent profit margin of 24.7%.
- Profit CAGR of 26.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 14.84B | 14.36B | 13.86B | 13.52B | 14.95B |
| Cost of Revenue | 3.32B | 3.54B | 3.61B | 3.46B | 3.71B |
| Gross Profit | 11.51B | 10.82B | 10.25B | 10.06B | 11.24B |
| Operating Expenses | 6.65B | 6.32B | 6.63B | 5.83B | 6.49B |
| Operating Income | 4.86B | 4.50B | 3.62B | 4.24B | 4.75B |
| EBITDA | 6.08B | 5.84B | 5.07B | 5.41B | 6.13B |
| Interest Expense | 289.00M | 281.00M | 304.00M | 343.00M | 462.00M |
| Pretax Income | 4.53B | 4.20B | 3.22B | 3.84B | 4.27B |
| Tax Provision | 507.00M | 266.00M | 814.00M | 683.00M | 1.01B |
| Net Income | 4.04B | 3.93B | 2.41B | 3.16B | 3.26B |
| Diluted EPS | 2.06 | 2.02 | 1.25 | 1.65 | 1.71 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 43.46B | 46.66B | 51.72B | 56.67B |
| Cost of Revenue | - | 11.58B | 12.47B | 12.83B | 13.70B |
| Gross Profit | - | 31.88B | 34.19B | 38.90B | 42.98B |
| Operating Expenses | - | 23.93B | 24.42B | 24.35B | 25.33B |
| Operating Income | - | 7.95B | 9.77B | 14.54B | 17.64B |
| EBITDA | - | 14.68B | 18.25B | 20.71B | 22.82B |
| Interest Expense | - | 800.00M | 855.00M | 1.01B | 1.14B |
| Pretax Income | - | 7.18B | 9.12B | 13.64B | 16.35B |
| Tax Provision | - | 1.13B | 551.00M | 1.70B | 2.38B |
| Net Income | - | 6.96B | 14.85B | 11.94B | 13.98B |
| Diluted EPS | - | 3.17 | 7.10 | 5.87 | 7.15 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 117.45B | 99.94B | 102.25B | 110.95B |
| Current Assets | - | 36.91B | 30.48B | 29.70B | 30.46B |
| Cash & Equivalents | - | 7.52B | 13.39B | 11.46B | 11.44B |
| Inventory | - | 7.17B | 5.91B | 5.72B | 6.27B |
| Receivables | - | 8.07B | 7.11B | 7.42B | 8.94B |
| Total Liabilities | - | 58.03B | 53.20B | 58.12B | 64.40B |
| Current Liabilities | - | 28.66B | 26.39B | 28.69B | 27.28B |
| Long Term Debt | - | 20.24B | 18.44B | 21.37B | 27.93B |
| Total Debt | - | 27.91B | 26.35B | 31.26B | 35.38B |
| Total Equity | - | 59.34B | 46.67B | 44.05B | 46.13B |
| Shares Outstanding | - | 2.40B | 2.28B | 2.19B | 2.11B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 14.24B | 14.46B | 17.62B | 19.14B |
| Investing Cash Flow | - | 1.47B | 5.60B | -7.51B | -4.88B |
| Financing Cash Flow | - | -20.56B | -14.28B | -11.74B | -14.87B |
| Capital Expenditure | - | -2.24B | -2.75B | -3.81B | -3.90B |
| Free Cash Flow | - | 12.00B | 11.71B | 13.80B | 15.24B |
| Net Change in Cash | - | -4.86B | 5.78B | -1.64B | -600.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 73.4% | 73.3% | 75.2% | 75.8% |
| Operating Margin % | - | 18.3% | 20.9% | 28.1% | 31.1% |
| Net Margin % | - | 16.0% | 31.8% | 23.1% | 24.7% |
| ROE % | - | 11.7% | 31.8% | 27.1% | 30.3% |
| ROCE % | - | 8.9% | 13.3% | 19.8% | 21.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVS
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5oRllyQi14b3ZkUWN4TVRPSUNpUXZxbkFaSE1PTDZGWldOMDJpTlZMaUM4V3dTQ2FtaGZ1cmk5dnNOdWJ4Q2JYUGkxVm1VVFR0M2FBcDFXSDExQQ?oc=5" target="_blank">NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NV…
Novartis: The Buy Thesis Is Back (Rating Upgrade) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQSTNiQzhzN1lQUUk4bWREaUxQYmphUWl2YjNXY0k4NzJaTmRaWmY1eHBDR3lWRnM0azctaWdpYThicmk1ZFhOQzQ3dUdsajVNUTF2a0JCbXFyNm9YLWRPQUZrNTk4Q1RSaXRIcF9aOVhRRng1ZE5yTDhWWDRUQXNkRlo4N1EtaW1Id3ZFNW…
Novartis AG (NVS): 7 Best Longevity and Anti-Aging Stocks to Buy - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPckZUd2pEUzRHRV9vSDhhWWxEUDNHM3VMOUw5aHhoN0Z0S1FsY2t6ZjhQMEpNVlF3RVdIWjU2Rlh6X2JUd0t3U0tuV2xmUHhXUG9SZTlzTV9KcmJDaXMyODA4Skk4Z254QkhHdE5mNGl5MWczWlV0V3F3R0ZjZnZuS1NYb0JiTHRxdWcw?o…
Why Novartis (NVS) Stock Fell Today - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE9Ca09ueVR1V0hhMVBkbGs3MzBPZy16c3pvdWt5LU93VE1ybV82a0VZRFBmSUR3Z3JvUHgyLU1yU1NINWtNRXU5THhtSTNsUzlFNHdmeFNKVjRwYmtWZ3gxMXNXZTc3NWZfV1c2emRFWG1KaFhRTklvdFE1aVg?oc=5" target="_blank">…
Novartis AG Stock (NVS) Moved Up by 4.20% on Jun 11: What Investors Need To Know - TradingKey
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOWlpQMU1uaG9IdTZWc1MwbkhFeG1VWW1seEpNckUyb2JWX1RWa2NPMGtuazNrNmxlVWFnTjJrWnRYelZ4OEdfclFocUlFTVR3MGRnUDNPdnU5ZDVkSjd0alBBSmlRTGVseVZnUm83b3h0VUVKNl9XZXZsVzR6d29ic3dtU2JCb2pVdFE?oc…
Stocks making the biggest moves premarket: General Motors, 3M, Novartis, Nebius & more - CNBC
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQQmxxbm5FR3dLQkc4Vks5dHFrSUxVT3NDMmZaZWsydWs1WG5JWklvR1VibkpCcU1mYVMzLUJyLU9UWGxPQk1zM3h0S0dDZHpDMno1Z3FYWnJoY2I5TXhDSVVDV1N4dGMzSDVySG5ZZzZVQTJCU1c4aHhIVmpIdVJVVWNuSXV1cm1EcWh2dG…
NVS — Frequently Asked Questions
What is the current share price of NVS?
As of 2026-08-05 17:25 PDT, NVS trades at $154.44 on NASDAQ/NYSE. Its 52-week range is $110.15 to $163.64.
What is the market capitalisation of NVS?
NVS has a market capitalisation of $326.24B on NASDAQ/NYSE.
What is the P/E ratio of NVS?
NVS trades at a trailing price-to-earnings (P/E) ratio of 21.60. Its price-to-book (P/B) ratio is 7.07.
What is the return on equity (ROE) of NVS?
NVS has a return on equity (ROE) of 30.31%. Its return on capital employed (ROCE) is 21.09%.
Is NVS a good stock to buy?
This page provides a data-driven analysis of NVS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.